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Purpose: Obesity is a risk factor for asthma and type II diabetes. Peroxisome prolif-
erator-activated receptor (PPAR)-γ has been suggested to regulate inflammatory re-
sponses in diabetes and asthma. We investigated whether PPAR-α, PPAR-γ, adipo-
nectin receptors (AdipoR1, AdipoR2), leptin, and tumor necrosis factor (TNF)-α are 
expressed in rat lung tissues and whether the expression differs between obese Otsu-
ka Long-Evans Tokushima Fatty (OLETF) and lean Long Evans Tokushima Otsuka 
(LETO) rats. Materials and Methods: Obese and lean rats were given with a high 
fat diet or a 30% restricted diet for 32 weeks, and their blood glucose levels and 
weights were monitored. After 32 weeks, mRNA levels of PPAR-α, PPAR-γ, Adi-
poR1, AdipoR2, leptin, and TNF-α in lung tissues were measured using real time 
PCR. Results: PPAR-α, PPAR-γ, AdipoR1, AdipoR2, leptin, and TNF-α were ex-
pressed in both obese and lean rat lung tissues. Increased serum glucose levels on in-
traperitoneal glucose tolerance testing and a higher weight gain at 32 weeks were ob-
served in OLETF control rats compared to OLETF diet restricted rats. PPAR-γ 
expression was markedly elevated in obese control and diet restricted rats compared 
to lean rats, although PPAR-γ expression in obese rats was not affected by diet re-
striction. Leptin was highly expressed in OLETF rats compared to LETO rats. 
TNF-α expression was enhanced in OLETF control rats compared LETO diet re-
stricted rats, and decreased by diet restriction. PPAR-α, AdipoR1, and AdipoR2 ex-
pression were not significantly different between obese and lean rats. Conclusion: 
PPAR-γ was highly expressed in the lung tissues of obese rats and may be a novel 
treatment target for regulating lung inflammation associated with obesity.
Key Words:    Obesity, peroxisome proliferator activated receptor, adiponectin re-
ceptor, lung, leptin, TNF-alpha 
INTRODUCTION
Obesity is a significant health problem worldwide and its incidence has more than 
doubled during the last 20 years.1 Obesity is a leading risk factor for the develop-
ment of diabetes, cardiovascular disease, and malignancies, and also has an impact Su Jin Hwang, et al.
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lean subjects. The goal of this study was to determine 
whether PPAR-α, PPAR-γ, adiponectin receptor 1 (Adi-
poR1), AdipoR2, leptin, and TNF-α were expressed in rat 
lung tissues and whether their mRNA levels were different 
between obese and lean rats.
MATERIALS AND METHODS
Animals 
Animal experiments were conducted in accordance with 
Kangbuk Samsung Hospital Guide for the Care and Use of 
Laboratory Animals. Four week old male obese, prediabetic 
rats, Otsuka Long-Evans Tokushima Fatty (OLETF) rats and 
their lean non-diabetic counterparts, Long Evans Tokushima 
Otsuka (LETO) rats, were supplied by Otsuka Pharmaceu-
tical (Tokushima, Japan). The OLETF rats were initially 
characterized by late onset hyperglycemia and mild obesity, 
and have been studied as a model of non insulin dependent 
diabetes mellitus.23 
The rats were divided into six groups with approximately 
equal mean body weights: the LETO control group (n=6); 
the LETO diet restriction group (n=6); the OLETF control 
group (n=6); and the OLETF diet restriction group (n=6). 
The control groups were given with a 45% high fat diet, 
while the diet restriction groups with a 30% restricted diet 
for 32 weeks.
The animals were housed individually in cages at a con-
stant temperature (20-22°C) and humidity (60%) with a 
12-hour-light and 12-hour-dark cycle. They had free access 
to water and rat chow until the age of 32 weeks. Body weight 
and food intake were checked twice per week and intraperi-
toneal glucose tolerance testing was performed at 32 weeks 
of diet administration. The animals were sacrificed by decap-
itation at 32 weeks of treatment, and their lung tissues were 
rapidly removed. 
 
 Intraperitoneal glucose tolerance testing  
The serum glucose concentration was monitored using in-
traperitoneal glucose tolerance testing (IPGTT) in the 
OLETF control and diet restricted rats as well as in the LETO 
control and diet restricted rats. The rats were injected intraper-
itoneally with glucose solution (2 g/kg, 50% sterile glucose 
solution). Blood samples were drawn from the tail vein at 0, 
30, 60, 90, and 120 minutes after glucose administration. 
Blood glucose levels were measured using a glucometer (Ac-
cu-Chek-Performa, Roche Diagnostics, Penzberg, Germany).
on respiratory diseases such as asthma, chronic obstructive 
pulmonary disease as well as obesity hypoventilation syn-
drome and sleep apnea.2 Furthermore, obesity has been re-
ported to increase the prevalence and severity of asthma 
and also influences lung function.3 A recent animal study 
showed a relationship between obesity and asthma.4 
The influence of obesity on lung tissue involves the in-
flammatory changes in the lung microenvironment. It induc-
es a chronic, low-grade systemic inflammation, characterized 
by an increase in circulating leukocytes and proinflammatory 
cytokines such as interleukin (IL)-6, tumor necrosis factor 
(TNF)-α, resistin, free fatty acids, and leptin.1,5-7 These pro-
teins can originate from the adipose tissue itself, leading to 
systemic inflammation as well as airway inflammation.8 
Adiponectin, a fat tissue-induced hormone, is negatively 
associated with obesity, while leptin is positively related to 
obesity. In children with obesity, serum leptin levels are ele-
vated, which is decreased by weight reduction.9 On the oth-
er hand, serum adiponectin levels decrease in obese chil-
dren, and adiponectin mRNA expression from adipose 
tissue has been shown to be inversely associated with obe-
sity.10 Adiponectin has also been reported to have anti-in-
flammatory effects and down-regulates vascular smooth 
muscle cell proliferation in the presence of obesity.11 
Peroxisome proliferator-activated receptors (PPARs) be-
long to a family of ligand-activated transcription factors and 
include the nuclear hormone receptor family related to reti-
noid, glucocorticoid, and thyroid hormone receptors.12 
PPAR-α is highly expressed in the liver, heart, kidney, and 
skeletal muscle.13 PPAR-γ is expressed in the lung epitheli-
um, submucosa, and airway smooth muscle. PPAR-α and 
PPAR-γ are also expressed in alveolar macrophages and air-
way epithelial cells.14 PPAR-γ ligands have been shown to 
inhibit the release of pro-inflammatory cytokines from acti-
vated macrophages and airway epithelial cells.15,16 Further-
more, PPAR-γ ligands inhibit vascular smooth muscle cell 
proliferation, and induce apoptosis in endothelial cells, vas-
cular smooth muscle,17 T lymphocytes and macrophages.18 
Inflammation plays a critical role in asthma, and inhaled 
corticosteroids, which are the most potent anti-inflammato-
ry medication have been used as the first line asthma treat-
ment during the last 20 years.19,20 However, obesity can al-
ter the asthma phenotype into a more difficult-to-control 
and steroid-resistant type of asthma.21,22 This may be caused 
by different characteristics of the lung inflammation in 
obese asthmatic patients. Thus, it is critical to understand 
the differences in lung inflammation between obese and PPAR-γ Expression in Lung Tissue of Obese Rats
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thermal cycling profile consisted of a preincubation step at 
95°C for 10 minutes, followed by 45 cycles of a 95°C dena-
turation step for 10 seconds, a 55°C annealing step for 1 min-
ute, and a 72°C extension step for 4-9 seconds. At the end of 
the PCR, a melting curve analysis was performed by gradu-
ally increasing the temperature from 65°C to 95°C (0.2°C/s) 
to confirm the amplification specificity of the PCR products. 
The mRNA levels were corrected using the transcription lev-
el of the β-actin as an internal standard.
Statistical analysis 
Statistical analysis was performed using GraphPad Prism 
software 5.0 (GraphPad Software, San Diego, CA, USA). 
Comparisons of PPAR-α, PPAR-γ, AdipoR1, AdipoR2, 
leptin, and TNF-α mRNA concentrations between two 
groups were analyzed using Student t-test. p<0.05 was con-
sidered significant.
RESULTS
Body weight
There were no differences in the baseline body weight be-
tween OLETF control rats and OLETF diet restricted rats, 
and between LETO control rats and LETO diet restricted 
rats at 0-week. The initial mean body weights of the LETO 
control and diet restricted rats were 394 g and 399 g, re-
spectively, and the mean body weights of the OLETF control 
and diet restricted rats were 460 g and 467 g, respectively. 
OLETF control rats had an increase of weight by 48.9% 
and the OLETF diet restricted rats had an increase of weight 
by 5% at 32 weeks of treatment. The LETO control rats had 
a 31.9% weight gain whereas the LETO diet restricted rats 
had a 2.2% weight gain at the end of treatment. At 32 
weeks of treatment, the mean body weight showed a signif-
icant increase in OLETF control rats compared to the 
OLETF diet restricted rats and in the LETO control rats 
compared to the LETO diet restricted rats (Fig. 1).
Intraperitoneal glucose tolerance testing
The serum glucose concentrations were significantly higher in 
the OLETF control rats (p<0.05), then the OLETF diet re-
stricted rats and the LETO groups at all study time points (ex-
cept for the fasting serum glucose at 0 min), measured after 
intraperitoneal glucose load. For the OLETF control rats, the 
mean blood glucose level was 230 mg/dL at 30 minutes after 
glucose administration and 215 mg/dL at 120 minutes (Fig. 2).   
RNA analysis and quantitative real time PCR for 
PPAR-α, PPAR-γ, AdipoR1, AdipoR2, Leptin, and 
TNF-α 
The lung tissue was ground and homogenized with liquid 
nitrogen in a mortar. Then, the mRNA expression was ana-
lyzed by real time reverse transcriptase (RT) PCR; the ratio 
of mRNA copy number to β-actin mRNA copy number 
was determined. The total RNA was extracted, using TRI 
Reagent (Sigma Chemical Co., St. Louis, MO, USA), ac-
cording to the manufacturer’s instructions. To summarize 
the real time PCR, 1 mL of TRI-reagent was blended in 
lung tissue and homogenized by ultrasound; 200 µL of chlo-
roform was added and the solution was vigorously mixed. 
Then, the sample was centrifuged for 15 minutes, and the 
RNA was subjected to reverse transcription using the cold 
Strand cDNA Synthesis Kit (ThermoFisher Scientific, Vilni-
us, Lithuania) for 60 minutes at 42°C, and for 10 minutes at 
70°C. The FastStart Taq DNA polymerase (LightCycler 
FastStart DNA Master SYBR Green I, Roche Diagnostics, 
Germany) and 3 mM MgCl2 were added, and 0.4 μM prim-
er was amplified in the LightCycler 480 Instrument (Roche 
Molecular Biochemicals, Penzberg, Germany).
The following primers were used: for the rat AdipoR1, 
the forward primer was 5’-AGATGGGCTGGTTCTTC 
CTC-3’, and the reverse primer was 5’-CAGTGCATTT-
GCCAGG-3’ (GenBank accession number: NM_207587); 
for the rat AdipoR2, the forward primer was 5’-ATGTTT-
GCCACCCCTCAGTA-3’, and the reverse primer was 
5’-CAGATGTCACATTTGCCAGG-3’ (GenBank acces-
sion number: NM_001037979); for the rat PPAR-α, the for-
ward primer was 5’-TTCGGAAACTGCAGACCT-3’, and 
the reverse primer was 5’-TTAGGAACTCTCGGGT-
GAT-3’ (GenBank accession number: NM_013196); for the 
rat PPAR-γ, the forward primer was 5’-TAGGTGTGATC 
TTAACTGTCG-3’, and the reverse primer was 5’-GCAT-
GGTGTAGATGATCTCA-3’ (GenBank accession num-
ber: NM_013124); for the rat TNF-α, the forward primer 
was 5’-GGGGCCACCACGCTCTTCTGTCTA-3’, and 
the reverse primer was 5’-CCTCCGCTTGGTGGTTTGC-
TACG-3’ (GenBank accession number: NM_012675); for 
the rat leptin, the forward primer was 5’-TTGTCACCAG-
GATCAATGACATTTG-3’, and the reverse primer was 
5’-ACAAACTCAGAATGGGGTGAAG-3’ (GenBank ac-
cession number: NM_013076); for the rat β-actin, the for-
ward primer was 5’-AGGTCATCACTATCGGCAAT-3’, 
and the reverse primer was 5’-ACTCATCGTACTCCT-
GCTTG-3’ (GenBank accession number: NM_031144). The Su Jin Hwang, et al.
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ed by diet restriction. However, the PPAR-γ mRNA levels 
were significantly elevated in the OLETF control rats com-
pared to the LETO control and the LETO diet restricted 
rats. The OLETF diet restricted rats showed higher PPAR-γ 
mRNA levels than the LETO diet restriction rats and the 
LETO control rats. However, there were no significant dif-
ferences in the PPAR-γ mRNA levels between the OLETF 
control and the OLETF diet restricted rats and between the 
LETO control and LETO diet restricted rats (Fig. 3).
The leptin mRNA levels were highly enhanced in the 
OLETF control rats compared to the LETO control and the 
LETO diet restricted rats. There was a decreasing tendency 
of leptin mRNA levels by diet restriction in OLETF rats, al-
though not statistically significant. TNF-α was highly ex-
pressed in lung tissue of the OLETF control rats compared 
to the LETO diet restriction rats, showing significant de-
crease by diet restriction in OLETF rats (Fig. 4).
DISCUSSION
The expression of PPAR-α, PPAR-γ, adiponectin receptors 
(AdipoR1, AdipoR2), leptin, and TNF-α was studied in rat 
lung tissues to determine whether their expressions were dif-
ferent between prediabetic, obese OLETF and lean LETO rat 
model. And the results demonstrated that PPAR-α, PPAR-γ, 
adiponectin receptors, leptin, and TNF-α were expressed in 
rat lung tissue, and that PPAR-γ, leptin, and TNF-α were 
highly expressed in obese rat lung tissue compared to lean rat 
AdipoR1, AdipoR2, PPAR-α, PPAR-γ, leptin, and TNF-α 
mRNA expression in the lung tissue of the study rats
AdipoR1, AdipoR2, PPAR-α, PPAR-γ, leptin, and TNF-α 
mRNA expression in the lung tissue of control and diet re-
stricted OLETF rats and the LETO rats were evaluated. Ad-
ipoR1 and AdipoR2 mRNA levels were not significantly 
different between the OLETF control rats and the LETO 
control rats, and were not influenced by diet restriction in the 
OLETF or the LETO rats. In addition, the PPAR-α mRNA 
levels were not significantly different between the OLETF 
control rats and the LETO control rats, and were not affect-
Fig. 1. Body weight changes between control rats and rats with 30% diet restriction. The weight gain of the OLETF control group was signif-
icantly higher than the other groups (p<0.05). The LETO control group showed a higher weight gain than the LETO diet restricted group. The 
OLETF diet restricted group had a greater weight gain than the LETO diet restricted group. *p<0.01 compared to the other groups. †p<0.05 
compared to LETO (30% diet-restriction). OLETF, Otsuka Long-Evans Tokushima Fatty; LETO, Long-Evans Tokushima Otsuka; C, control.
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over, PPAR-γ ligands inhibit PPAR-γ levels in the lung and 
the release of proinflammatory cytokines from activated 
macrophages, airway epithelial cells, and eosinophils, and 
decrease airway hyperreactivity, basement membrane thick-
ness, collagen deposition, and eosinophilia in murine models 
of asthma. Furthermore, PPAR-γ agonists reduced cigarette 
smoke-induced mucin production in the airway epithelial 
cells28 and a nebulized PPAR-γ agonist, ciglitazone, signifi-
cantly suppressed mucus secretion and collagen deposition 
in airway epithelial cells of allergen-challenged sensitized 
mice.29 In this regard, PPAR-γ might be a target for reduc-
ing airway inflammation and remodeling. 
There are only a few clinical studies for the therapeutic 
effect of PPAR-γ ligands in asthma.
lung tissue. 
The presence of PPARs has been demonstrated in a vari-
ety of cells associated with lung inflammation.24 PPAR-γ 
has been found in lung epithelial cells, smooth muscle cells, 
fibroblasts, endothelial cells, macrophages, eosinophils, T 
cells, B cells, and dendritic cells.14-16,25,26 Recent studies 
have shown that PPAR-γ has some beneficial effects with 
regard to the regulation of airway inflammation in asthma. 
PPAR-γ expression is augmented in the bronchial submu-
cosa, airway epithelium and smooth muscle in steroid-un-
treated asthma and has been associated with submucosal 
basement membrane thickening and collagen deposition. In 
addition, oral or inhaled steroids have been shown to down-
regulate PPAR-γ expression and airway remodeling.27 More-
Fig. 3. Adiponectin receptor 1, adiponectin receptor 2, PPAR-α, and PPAR-γ mRNA expressions in lung tissue of OLETF rats and LETO rats: 
each mRNA expression was measured by real time PCR. (A) AdipoR1 mRNA levels did not show significant differences among all 
groups. (B) AdipoR2 mRNA levels were not different in the four groups. (C) PPAR-α mRNA levels in the four groups showed no significant 
differences. (D) PPAR-γ mRNA levels showed marked increases in the OLETF control rats compared to the LETO control and diet restrict-
ed rats. However, PPAR-γ was not affected by diet restriction. *p<0.05. OLETF, Otsuka Long-Evans Tokushima Fatty; LETO, Long-Evans 
Tokushima Otsuka.
LETO control
LETO control
LETO control
LETO control
LETO diet
LETO diet
AdipoR1
PPAR-α
AdipoR2
PPAR-γ
LETO diet
LETO diet
OLETF control
OLETF control
OLETF control
OLETF control
OLETF diet
OLETF diet
OLETF diet
OLETF diet
0
0.0
0.0
0
1
0.5
0.5
1
2
1.0
1.0
2
3
1.5
1.5
3
4
2.0
2.0
4
A
d
i
p
o
1
/
β
-
a
c
t
i
n
 
m
R
N
A
(
R
e
l
a
t
i
v
e
l
y
 
d
e
n
s
i
t
y
 
u
n
i
t
)
P
P
A
R
-
α
/
β
-
a
c
t
i
n
 
m
R
N
A
(
R
e
l
a
t
i
v
e
l
y
 
d
e
n
s
i
t
y
 
u
n
i
t
)
A
d
i
p
o
2
/
β
-
a
c
t
i
n
 
m
R
N
A
(
R
e
l
a
t
i
v
e
l
y
 
d
e
n
s
i
t
y
 
u
n
i
t
)
P
P
A
R
-
γ
/
β
-
a
c
t
i
n
 
m
R
N
A
(
R
e
l
a
t
i
v
e
l
y
 
d
e
n
s
i
t
y
 
u
n
i
t
)
*
*
*
*
A
C
B
D
Fig. 4. Leptin and TNF-α mRNA expressions in lung tissue of OLETF rats and LETO rats: each mRNA expression was measured by real time 
PCR. (A) Leptin mRNA levels showed marked increase in the OLETF control rats compared to the LETO control and diet restricted rats. 
However, leptin was not affected by diet restriction. (B) TNF-α mRNA levels increased significantly in the OLETF control rats compared to 
the OLETF and LETO diet restricted rats. *p<0.05. OLETF, Otsuka Long-Evans Tokushima Fatty; LETO, Long-Evans Tokushima Otsuka.
LETO control LETO control LETO diet
Leptin TNF-α
LETO diet OLETF control OLETF control OLETF diet OLETF diet
0
2
4
6
8
10
0.0
0.5
1.0
1.5
2.0
2.5
L
e
p
t
i
n
/
β
-
a
c
t
i
n
 
m
R
N
A
(
R
e
l
a
t
i
v
e
l
y
 
d
e
n
s
i
t
y
 
u
n
i
t
)
T
N
F
-
α
/
β
-
a
c
t
i
n
 
m
R
N
A
(
R
e
l
a
t
i
v
e
l
y
 
d
e
n
s
i
t
y
 
u
n
i
t
) * *
A B
*
*Su Jin Hwang, et al.
Yonsei Med J   http://www.eymj.org   Volume 52   Number 3   May 2011 500
regulate PPAR-γ expression in mononuclear cells.40 In the 
present study, leptin expression in the lung of obese rats was 
highly enhanced compared to lean rats. The origin of leptin 
and TNF-α in obesity has currently been known to be adi-
pose tissue. Our results imply that TNF-α and leptin are also 
expressed on lung tissue of obese rats. We are not certain 
whether TNF-α or leptin influences PPAR-γ expression in 
obesity, since there are no data available. Nevertheless, our 
results may imply that increased proinflammatory cytokines 
in lung tissue are related to PPAR-γ expression in obesity.
Adiponectin decreases obesity and may play an anti-in-
flammatory role in obesity-related diseases.11 Adiponectin 
receptors (AdipoR1 and AdipoR2) are reported to be ex-
pressed in airway smooth muscle cells.38 However, there 
have been no reported data which compared the expression 
of adiponectin receptors in obese and lean rat lung tissues. 
The present results showed that adiponectin receptors were 
expressed in rat lung tissue, although the mRNA levels did 
not differ in the lean compared to obese states. 
The present study was limited by relatively small number 
of subjects and the absence of an asthma model. Neverthe-
less, this study is the first trial to demonstrate that PPAR-γ, 
leptin, and TNF-α were highly expressed in the lung tissue 
of obese rats, and that the expression of adiponectin recep-
tors and PPAR-α were not affected by obesity. In addition, 
weight reduction was found to have no effect on PPAR-γ 
expression, although it reduced TNF-α expression. This sug-
gests that leptin, TNF-α, and PPAR-γ are highly expressed 
in lung tissue of obesity, and that PPAR-γ, but not PPAR-α 
or adiponectin receptors, might be a novel treatment target 
for regulating lung inflammation associated with obesity. 
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